Digital Health Company eMeda?? Launches At-Home COVID-19 Rapid Testing

MIAMI, Jan. 23, 2021 /PRNewswire/ --A eMeda??, a digital health company democratizing healthcare through digital point-of-care solutions, announced it will begin to administerA the FDA-authorized, at-home symptomatic BinaxNOWa?? COVID-19 Ag Card rapid home test to 100,000 qualified individuals across the U.S. who order through eMed.comA beginning today. These 100,000 individuals will be among the first to use eMed's transformative approach to at-home testing.A At $25 each, the eMed-administered rapid testsA are the first virtually guided, at-home tests available and the most affordable testing option on the market with authenticated results automatically reported to public health authorities."We are thrilled to share with the public the eMed digital health platform is coming to the market in just over a month since receiving FDA authorization for truly at-home COVID-19 rapid testing," said Dr. Patrice Harris, eMed CEO. "Our team has been working tirelessly to put tests in the hands of people across our nation, starting with large employers and states. Today's announcement is the first step in ensuring the general public also has access to affordable, at-home testing."During a time when COVID-19 testing is needed most, consumers will no longer have to rush to COVID-19 testing sites between daily appointmentsA and tasks, nor will they have to wait in long lines for testing, risking potential exposure to the coronavirus.